| 产品详情 |
| Edit |   |
|---|
| Product Name | CCG-100602 |
|---|
| Description | Purity >98%. The Rho family of small GTPases play an important role in transduction of cell signaling events associated with several human cancers. CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. The site of inhibition in the pathway is not precisely defined but CCG-1423 appears to act on some aspect of the interaction of SRF with its transcriptional cofactor megakaryoblastic leukemia 1 (MKL1) at a point upstream of DNA binding. CCG-100602 is a CCG-1423 analog developed for improved selectivity, potency, and attenuated cytotoxicity relative to its parent compound. CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells with an IC50 value of 9.8 µM. At 100 µM, CCG-100602 demonstrates 72% inhibition of PC-3 cell invasion into a model of metastasis, exhibiting an efficacy:toxicity profile superior to that of CCG-1423 at 10 µM. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 1-[3,5-bis (trifluoromethyl)benzoyl]-N-(4-chlorophenyl)-3-piperidinecarboxamide |
|---|
| Gene, Accession, CAS # | CAS: 1207113-88-9 |
|---|
| Catalog # | LS-H7027 |
|---|
| Price | |
|---|
| Order / More Info | CCG-100602 from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|